Currently there are six hyaluronate acid products that have been approved by the U.S. Food and Drug Administration to treat osteoarthritis of the knee: Euflexxa®, Hyalgan®, Orthovisc®, Supartz®, Synvisc®, and Synvisc-One®.
IBC has designated Euflexxa®, Synvisc®, and Synvisc-One® as our preferred hyaluronate acid products for treatment of osteoarthritis of the knee. These three preferred brands were selected based on their demonstrated cost-effectiveness to the plan. Choosing one of these preferred brands does not affect the member’s cost-sharing for the drug.
IBC encourages providers to choose one of these three preferred brands when treating members with osteoarthritis of the knee.
Read the complete article in the June edition of Partners in Health UpdateSM.